Menu Close

One step back: Why the new Alzheimer’s plaque-attack drugs don’t work

On Jan. 31, aducanumab, a pricey drug approved for treatment of early-stage Alzheimer’s disease, was withdrawn from the market. And in early March, the Food and Drug Administration delayed its decision regarding whether to approve a separate, closely similar drug. A prescient commentary by Stanford Medicine neurologist Mike Greicius, MD, in the Journal of Alzheimer’s Disease goes a long way toward explaining why.